
... BIBLIOGRAPHY ...

- Ambrecht U, Abucar A, Hameeteman W, et al. Treatment of reflux oesophagitis of moderate and severe grade with ranitidine or pantoprazole—comparison of 24 hour intragastric and esophageal pH. *Aliment Pharmacol Ther* 1997;11:959-965.
- Bardhan KD, Morton D, Slater DN, et al. Pantoprazole-based 10-day triple therapy is effective in *Helicobacter pylori* eradication. *Aliment Pharmacol Ther* 1998;12:185-189.
- Bardhan KD. The role of proton pump inhibitors in the treatment of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 1995;9:15-25.
- Beck IT, Champion MC, Lemire S, et al. The second Canadian Consensus Conference on the Management of Patients with Gastroesophageal Reflux Disease. *Can J Gastroenterol* 1997;11(suppl B):7B-20B.
- Becker DJ, Sinclair J, Castell DO, et al. A comparison of high and low fat meals on postprandial esophageal acid exposure. *Am J Gastroenterol* 1989;84:782-786.
- Bell NJ, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. *Digestion* 1992;51:59-67.
- Biliesatii H, Huber R, Steinijans VW, Kunz K, Wurst W. Pantoprazole does not interact with nifedipine in man under steady-state conditions. *Int J Clin Pharmacol Ther* 1996; 34:51-55.
- Bochenek W, Miska D, Beg M. The Pantoprazole US Study Group. Efficacy of pantoprazole in reflux erosive esophagitis is dose related. *Digestion* 1998;59(suppl 3):601.
- Breuel HP, Horak J, Horejsova M, et al. Pantoprazole in patients with varying degree of liver impairment in comparison to healthy controls. *Gastroenterology* 1998;114:A6 [Abstract].
- Broussard CN, Richter JE. Treating gastro-oesophageal reflux disease during pregnancy and lactation: What are the safest therapy options? *Drug Safety* 1998;4:325-337.
- Brunner G, Harke U. Long-term therapy with pantoprazole in patients with peptic ulceration resistant to extended high-dose ranitidine treatment. *Aliment Pharmacol Ther* 1994;8:59-64.
- Cameron AH, Zinsmeister AR, Ballard DH, Carney JA. Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. *Gastroenterology* 1990;99:918-922.
- Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus. *N Engl J Med* 1985;313:857-859.
- Castell DO, Richter JE, Robinson MJ, et al. Efficacy and safety of lansoprazole in the treatment of erosive oesophagitis. *Am J Gastroenterol* 1996;91:1749-1757.
- Catalano F, Branciforte G, Catanzaro R, et al. Comparative treatment of *Helicobacter pylori*-positive duodenal ulcer using pantoprazole at low and high doses versus omeprazole in triple therapy. *Helicobacter* 1999;4:178-184.
- Ciocola AA, McSorley DJ, Turner K, et al. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. *Am J Gastroenterol* 1999;7:1834-1840.
- Collen MJ, Abdulian JD, Chen YK. Gastroesophageal reflux disease in the elderly: More severe disease that requires aggressive therapy. *Am J Gastroenterol* 1995;90:1053-1057.
- Cremer M, Lambert R, Lamers CBHW, et al. A double blind study of pantoprazole and ranitidine in treatment of acute duodenal ulcer. *Dig Dis Sci* 1995;40:1360-1364.
- Creteur V, Thoeni RF, Federle MP, et al. The role of single- and double-contrast radiography in the diagnosis of reflux esophagitis. *Radiology* 1986;147:71-75.
- Dekkers CP, Beker JA, Thjodleifsson B, et al. Double-blind placebo-controlled comparison of rabeprazole 20 mg vs omeprazole 20 mg in the treatment of erosive or ulcerative gastroesophageal reflux disease. *Aliment Pharmacol Ther* 1999;13:49-57.
- DeMeester TR, Peters JH, Bremner CG, Chandrasoma P. Biology of gastroesophageal reflux disease: Pathophysiology relating to medical and surgical treatment. *Annu Rev Med* 1999;50:469-506.
- Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management. *Gut* 1999;44(suppl 2):S1-S16.

... BIBLIOGRAPHY ...

- Dent J, Yeomans ND, MacKinnon M, et al. Omeprazole versus ranitidine for prevention of relapse in reflux esophagitis: A controlled double blind trial of their efficacy and safety. *Gut* 1994;35:590-598.
- DeVault KR, Castell DO. Current diagnosis and treatment of gastroesophageal reflux disease. *Mayo Clin Proc* 1994;69:867-876.
- DeVault KR, Castell DO. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology. *Arch Intern Med* 1995;155:2165-2173.
- DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. *Am J Gastroenterol* 1999;94:1434-1442.
- Dimenas E. Methodological aspects of evaluation of quality of life in upper gastrointestinal diseases. *Scand J Gastroenterol* 1993;28:18-21.
- Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: A prospective study of 170 patients followed 4.8 years. *Am J Gastroenterol* 1997;92:212-215.
- Dupas JL, Houche PH, Giret-d'Orsay G, Samoyeau R. Pantoprazole versus lansoprazole in patients with reflux esophagitis. Meta-analysis of two French studies. *Digestion* 1998;59(suppl 2):604 [Abstract].
- Earnest DL, Robinson M. Treatment advances in acid secretory disorders: The promise of rapid symptom relief with disease resolution. *Am J Gastroenterol* 1999;94(suppl):S18-S24.
- Escourrou J, Deprez P, Saggiaro A, et al. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis. *Aliment Pharmacol Ther* 1999;13:1481-1491.
- Falk GW. Reflux disease and Barrett's esophagus. *Endoscopy* 1999;31:9-16.
- Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short-course of omeprazole in patients with noncardiac chest pain. *Gastroenterology* 1999;115:42-49.
- Fass R, Ofman JJ, Gralnek IM, et al. Clinical and economic assessment of the omeprazole test in patients with symptoms suggestive of gastroesophageal reflux disease. *Arch Intern Med* 1999;159:2161-2168.
- Fendrick AM, Blitz SG. Gastroesophageal reflux: Therapy considerations after failure of low-dose, nonprescription H₂RAs. *Formulary* 1999;34:234-248.
- Ferioli E, Oliveira RB, Matsuda NM, et al. Aging, esophageal motility, and gastroesophageal reflux. *J Am Geriatr Soc* 1998;46:1534-1537.
- Fitton A, Wiseman L. Pantoprazole: A review of its pharmacological properties and therapeutic use in acid-related disorders. *Drugs* 1996;51:460-482.
- Freston JW, Rose PA, Heller CA, et al. Safety profile of lansoprazole: The US clinical trial experience. *Drug Safety* 1999;20:195-205.
- Freston JW. Long-term acid control and proton pump inhibitors: Interactions and safety issues in perspective. *Am J Gastroenterol* 1997;92:51S-57S.
- Galmiche JP, Hanssen J. The pathophysiology of gastroesophageal reflux disease: An overview. *Scand J Gastroenterol* 1995;211:7-18.
- Garnett WR, Garabedian-Ruffalo SM. Identification, diagnosis and treatment of acid related diseases in the elderly: Implications for long-term care. *Pharmacotherapy* 1997;17:938-958.
- Garnett WR. Considerations for long-term use of proton pump inhibitors. *Am J Health Syst Pharm* 1998;55:2268-2279.
- Gastrointestinal disorders. In: Beers MH, Berkow R, eds. *The Merck Manual*, 17th ed. Whitehouse Station, NJ: Merck Research Laboratories; 1999.
- Gough AL, Long RG, Cooper BT. Lansoprazole versus ranitidine in the maintenance treatment of reflux oesophagitis. *Aliment Pharmacol Ther* 1996;10:529-539.
- Goyal RK. Diseases of the esophagus. In: Fauci AS, Braunwald E, Isselbacher, et al, eds. *Harrisons Principles of Internal Medicine*, Vol. 2. New York, NY: McGraw Hill; 1998.
- Harris RA, Kuppermann M, Richter JE, et al. Proton pump inhibitor or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: A cost-effective analysis. *Am J Gastroenterol* 1997;92:2179-2187.

... BIBLIOGRAPHY ...

- Hartmann M, Ehrlich A, Fuder H, et al. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. *Aliment Pharmacol Ther* 1998;12:1027-1032.
- Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. *Aliment Pharmacol Ther* 1998;12:1235-1240.
- Hetzel D. Acid pump inhibition. The treatment of gastroesophageal reflux. *Aust Fam Physician* 1998;27:487-491.
- Heudebert GR, Marks R, Wilcox CM, et al. Choice of long-term strategy for the management of patients with severe esophagitis: A cost-utility analysis. *Gastroenterology* 1997;112:1078-1086.
- Hotz J, Plein K, Schonekas H, et al. Pantoprazole is superior to ranitidine in the treatment of acute gastric ulcer. *Scand J Gastroenterol* 1995;30:111-115.
- Humphries TJ, Merritt GJ. Review article: Drug interactions with agents used to treat acid-related diseases. *Aliment Pharmacol Ther* 1999;13(suppl 3):18-26.
- Hunt RH. Importance of pH control in the management of GERD. *Arch Intern Med* 1999;159:649-657.
- Ishizaki T, Horai Y. Review article: Cytochrome P450 and the metabolism of proton pump inhibitors—emphasis on rabeprazole. *Aliment Pharmacol Ther* 1999;12(suppl 3):27-36.
- Johnson LF, DeMeester TR. Evaluation of elevation of the head of the bed, bethanechol and antacid foam tablets on gastroesophageal reflux. *Dig Dis Sci* 1981;26:673-680.
- Johnsson F, Weywadt L, Solhaug JH, et al. One-week omeprazole treatment in the diagnosis of gastroesophageal reflux disease. *Scand J Gastroenterol* 1998;33:15-20.
- Johnson DA. Medical therapy of GERD: Current state of the art. *Hosp Pract* 1996;31:135-148.
- Judmaier G, Koelz JR, Pantoprazole-Duodenal Ulcer Study Group. Comparison of pantoprazole and ranitidine in the treatment of acute duodenal ulcer. *Aliment Pharmacol Ther* 1994;8:81-86.
- Kallen B. Delivery outcomes after use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. *Br J Obstet Gynaecol* 1998;105:877-881.
- Kastrup EK, Hebel SK, Rivard R, et al. *Drug facts and Comparisons*. St Louis, MO: Facts and Comparisons; 1999:304a-d.
- Katz PO, Castell DO. Gastroesophageal reflux disease during pregnancy. *Gastroenterol Clin North Am* 1998;27:153-167.
- Katz PO. Treatment of gastroesophageal reflux disease: Use of algorithms to aid in management. *Am J Gastroenterol* 1999;94(suppl):S3-S10.
- Kliem V, Bahlmann J. Pharmacokinetics of pantoprazole in patients with end-stage renal failure. *Nephrol Dial Transplant* 1998;13:1189-1193.
- Koehler RE, Weymean PJ, Oakley HF. Single- and double contrast techniques in esophagitis. *Am J Roentgenology* 1980;135:15-19.
- Koop J, Schepp W, Dammann HG, et al. Comparative trial of pantoprazole and ranitidine in the treatment of esophagitis. Results of a German multicenter study. *J Clin Gastroenterol* 1995;20:192-195.
- Kromer W, Horbach S, Luhmann R. Relative efficacies of gastric proton pump inhibitors: Their clinical and pharmacological basis. *Pharmacology* 1999;59:57-77.
- Kromer W. Similarities and differences in the properties of substituted benzimidazoles: A comparison between pantoprazole and related compounds. *Digestion* 1995; 56:443-454.
- Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and *Helicobacter pylori* infection in patients with reflux esophagitis treatment with omeprazole or fundoplication. *N Engl J Med* 1996;334:1018-1022.
- Kunz K, Arundell E, Cisternas M, Heaton A. Economic implications of self-treatment of heartburn/nonulcer dyspepsia with nonprescription famotidine in a managed care setting. *J Managed Care Pharm* 1996;2:263-271.
- Kuo WH, Kalloo AN. Reflux strictures of the esophagus. *Gastrointest Endosc Clin North Am* 1998;8:273-281.
- Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. *N Engl J Med* 1999;340:825-831.
- Lalkin A, Lobstein R, Addis A, et al. The safety of omeprazole during pregnancy: A multicenter prospective controlled study. *Am J Obstet Gynecol* 1998;179:727-730.

... BIBLIOGRAPHY ...

- Lamers CBHW. The changing role of H2 receptor antagonists in acid-related diseases. *Eur J Gastroenterol Hepatol* 1996;8:S3-S7.
- Langtry HD, Wilde MI. Lansoprazole: An update on its pharmacological properties and clinical efficacy in the management of acid-related disorders. *Drugs* 1997;54:473-500.
- Langtry HD, Wilde MI. Omeprazole: A review of its use in *Helicobacter pylori* infection, GERD, and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. *Drugs* 1998;56:447.
- Laparoscopic antireflux surgery for gastroesophageal reflux disease (GERD). Results of a consensus development conference held at the Fourth International Congress of the European Association for Endoscopic Surgery (E.A.E.S), Trondheim, Norway, June 21-24, 1996. *Surg Endosc* 1997;11:413-426.
- Lauritsen K, Rutgersson K, Bolling E. Omeprazole 20 mg or 40 mg daily for healing of duodenal ulcer: A double-blind comparative study. *Eur J Gastroenterol Hepatol* 1992;4:995-1000.
- Levin TR, Schmittiel JA, Kurz K, et al. Costs of acid-related disorders to a health maintenance organization. *Am J Med* 1997;103:520-528.
- Lew EA. Review article: Pharmacokinetic concerns in the selection of anti-ulcer therapy. *Aliment Pharmacol Ther* 1999;13(suppl 5):11-16.
- Lieberman DA, Oehlke M, Helfand M, the Gorege Consortium. Risk factors for Barrett's esophagus in community-based practice. *Am J Gastroenterol* 1997;92:1293-1297.
- Lind T, Megraud F, Unge P, et al. The MACH2 study: Role of omeprazole in eradication of *Helicobacter pylori* with 1-week triple therapies. *Gastroenterology* 1999;116:248-253.
- Lins RL, De Clerq I, Hartmann M, et al. Pharmacokinetics of proton pump inhibitor pantoprazole in patients with severe renal impairment. *Gastroenterology* 1994;106:A126 [Abstract].
- Lorf T, Ramadori G, Ringe B, Shwörer H. Pantoprazole does not affect cyclosporin A blood concentration kidney-transplant patients. *J Clin Pharmacol* 2000;55:733-735.
- Lundell L, Ott DJ, Hattlevakk J, et al. Omeprazole or antireflux surgery in the long term management of gastroesophageal reflux disease: Results of a multicenter, randomized, clinical trial. *Gastroenterology* 1998;114:A207.
- Mathias SD, Castell DO, Elkin EP, Matosian ML. Health-related quality of life of patients with acute erosive reflux esophagitis. *Dig Dis Sci* 1996;41:2123-2129.
- Mattox HE, Richter JE. Prolonged ambulatory esophageal pH monitoring in the evaluation of gastroesophageal reflux disease. *Am J Med* 1990;89:345-356.
- Mee AS, Rowley JL. Rapid symptom relief in reflux oesophagitis: A comparison of lansoprazole and omeprazole. *Aliment Pharmacol Ther* 1996;10:757-763.
- Meyer UA. Metabolic interactions of the proton pump inhibitors lansoprazole, omeprazole, and pantoprazole with other drugs. *Eur J Gastroenterol Hepatol* 1996;8(suppl 1):S21-S25.
- Meyers WF, Herbst JJ. Effectiveness of positioning therapy for gastroesophageal reflux. *Pediatrics* 1982;69:768-772.
- Mignon M, Vallot T. Acute treatment of duodenal ulcer: Experience with lansoprazole. *Aliment Pharmacol Ther* 1993;7:37-40.
- Modlin IM, Sachs R. *Acid-Related Diseases*. Munich, Germany: Schnetztor-Verlag GmbH D-Konstanz; 1998.
- Moosner J, Koop H, Porst H, Wubbolding H, Schneider A, Maier C. One-year prophylactic efficacy and safety of pantoprazole in controlling gastro-oesophageal reflux patients with healed reflux oesophagitis. *Aliment Pharmacol Ther* 1997;11:1087-1092.
- Mujica VR, Rao SSC. Recognizing atypical manifestation of GERD. Asthma, chest pain and otolaryngologic disorders may be due to reflux. *Postgrad Med* 1999;105:53-66.
- Mulder CJ, Dekker W, Gerretsen M, et al. Lansoprazole 30 mg versus omeprazole 40 mg in the treatment of reflux oesophagitis grade II, III and IV (a Dutch multicentre trial). *Eur J Gastroenterol Hepatol* 1996;8:1101-1106.
- Nielsen GL, Sorensen HT, Thulstrup AM, Tage-Jensen U, Olesen C, Ekboms A. The safety of proton pump inhibitors in pregnancy. *Aliment Pharmacol Ther* 1999;13:1085-1089.

... BIBLIOGRAPHY ...

- O'Connor HJ. Review article: *Helicobacter pylori* and gastro-oesophageal reflux disease—clinical implications and management. *Aliment Pharmacol Ther* 1999;13:117.
- O'Connor JFB, Singer ME, Richter JE. The cost-effectiveness of strategies to assess gastroesophageal reflux as an exacerbating factor in asthma. *Am J Gastroenterol* 1999;94:1472-1480.
- Orlando RD. Reflux esophagitis. In: Yamada T, Alpers DH, Laine L, Owyand CH, Powell DW, eds. *Textbook of Gastroenterology*, 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:1235-1263.
- Ormseth EJ, Wong RK. Reflux laryngitis: Pathophysiology, diagnosis, and management. *Am J Gastroenterol* 1999;10:2812-2817.
- Ott DJ, Chen YM, Gelfand DW, et al. Analysis of multiphasic radiographic examination for detecting reflux esophagitis. *Gastrointest Radiol* 1986;11:1-6.
- Ott DJ, Gelfand DW, Wu WC. Reflux esophagitis: Radiologic and endoscopic correlation. *Radiology* 1979;103:583-588.
- Ott DJ, Wu WC, Gelfand DW. Reflux esophagitis revisited: Prospective analysis of radiological accuracy. *Gastrointest Radiol* 1981;6:1-7.
- Ours TM, Kavuru MS, Schitz RJ, Richter JE. A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough. *Am J Gastroenterol* 1999;94:3131-3138.
- Pantoprazole: A third proton pump inhibitor. *Drug Ther Bull* 1997;35:93-94.
- Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: A controlled study in normal subjects. *Gastroenterology* 1998;115:1335.
- Pera M, Cameron AJ, Trastek VF, Carpenter JA, Zinsmeister AR. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. *Gastroenterology* 1993;104:510-513.
- Pillotto A, Leandro G, Franceschi M, et al. Rapid improvement of symptomatology with pantoprazole, amoxicillin and metronidazole in *Helicobacter pylori*-positive duodenal ulcer patients. *Hepatogastroenterology* 1999;46:245-251.
- Pisegna JR, Martin P, McKeand W, et al. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: A dose response study. *Am J Gastroenterol* 1999;94:2874-2880.
- Pope CE II. Acid-reflux disorders. *N Engl J Med* 1994;331:656-660.
- Proton pump inhibitor relabeling for cancer risk not warranted. *FDA Report*. November 11, 1996.
- Revicki D, Wood M, Maton PN, et al. The impact of gastroesophageal reflux disease on health-related quality of life. *Am J Med* 1998;104:252-258.
- Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors: Pharmacology and rationale for use in gastrointestinal disorders. *Drugs* 1998;56:307-335.
- Robinson M, Shaba B, Avner D, Jhalas N. A comparison of lansoprazole and ranitidine in the treatment of erosive esophagitis. *Aliment Pharmacol Ther* 1995;9:25-31.
- Robinson M. Review article: Current perspectives on hypergastrinemia and enterochromaffin-like-cell hyperplasia. *Aliment Pharmacol Ther* 1999;13(suppl 5):5-10.
- Sampliner RE. Practice guidelines on the diagnosis, surveillance and therapy of Barrett's esophagus. *Am J Gastroenterol* 1998;93:1028-1032.
- Sandmark S, Carlsson R, Fausa O, Lundell L. Omeprazole or ranitidine in the treatment of reflux esophagitis. Results of a double-blind, randomized, Scandinavian multicenter study. *Scand J Gastroenterol* 1988;23:625-632.
- Savarino V, Mela GS, Zentilin P, et al. Comparison of 24-hour control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. *Aliment Pharmacol Ther* 1998;12:1241-1247.
- Schepp W, Rehner M, Witzel L. A review of treatment of duodenal and gastric ulcers—pantoprazole vs. omeprazole. *Aliment Pharmacol Ther* 1994;8:53-57.
- Schlesinger PK, Donahue PE, Schmidt B, et al. Limitations of 24 hour intraesophageal pH monitoring in the hospital setting. *Gastroenterology* 1985;89:797-804.
- Schroeder PL, Filler SJ, Rasmirex B, Lazarchik DA, Vaezi MF, Richter JE. Dental erosion and acid reflux disease. *Ann Intern Med* 1995;122:809-820.

... BIBLIOGRAPHY ...

- Sellar RJ, Ott DJ, Heading RC. A sensitive test for gastro-oesophageal reflux. *Clin Radiol* 1987;38:303-307.
- Shafi MA, Fleischer DE. Risk factors of acute ulcer bleeding. *Hepatogastroenterology* 1999;46(26):727-731.
- Sharma P, Sampliner RE, Camargo E. Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. *Am J Gastroenterol* 1997;92:582-585.
- Sharma VK. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole. *Am J Health Syst Pharm* 1999;56(suppl 4):S18-S21.
- Sieg A, Sellinger M, Schlauch D, et al. Short-term triple therapy with lansoprazole 30 mg or 60 mg, amoxycillin and clarithromycin to eradicate *Helicobacter pylori*. *Aliment Pharmacol Ther* 1999;13:865-868.
- Sonnenberg A, Everhart JE. Health impact of peptic ulcer in the United States. *Am J Gastroenterol* 1997;92(4):614-620.
- Sonnenberg A, Inadomi JM, Becker A. Economic analysis of step-wise treatment of gastro-oesophageal reflux disease. *Aliment Pharmacol Ther* 1999;13:1003-1013.
- Sontag SJ, Kogut DG, Fleischmann R, et al. Lansoprazole heals erosive reflux esophagitis resistant to histamine H₂-receptor antagonist therapy. *Am J Gastroenterol* 1997;92:429-437.
- Spechler SJ, Goyal RK. Barrett's esophagus. *N Engl J Med* 1986;315:362-371.
- Spechler SJ, Robbins AH, Runbins HB, et al. Adenocarcinoma and Barrett's esophagus: An overrated risk? *Gastroenterology* 1984;87:927-933.
- Steinijs VW, Huber R, Hartmann M, et al. Lack of pantoprazole drug interactions in man: An updated review. *Int J Clin Pharmacol Ther* 1996;34:243-262.
- Swan SK, Hoyumpa AM, Merritt GJ. Review article: The pharmacokinetics of rabeprazole in health and disease. *Aliment Pharmacol Ther* 1999;13(suppl 3):11-17.
- Tew S, Jamieson GG, Pilowski I, Myers J. The illness behavior of patients with gastroesophageal reflux disease with and without endoscopic esophagitis. *Dis Esophagus* 1997;10:9-15.
- Thjodleifsson B, Cockburn I. Review article: Rabeprazole's tolerability profile in clinical trials. *Aliment Pharmacol Ther* 1999;13(suppl 5):17-23.
- Thomson AB, Chiba N, Armstrong D, et al. The second Canadian gastroesophageal reflux disease consensus: Moving forward to new concepts. *Can J Gastroenterol* 1998;12:551-556.
- Timmer R, Breumelhof R, Nadorp JHSM, et al. Oesophageal motility and gastro-oesophageal reflux before and after healing of reflux oesophagitis. A study using 24 hour ambulatory pH and pressure monitoring. *Gut* 1994;35:1519-1522.
- Toohill RJ, Kuhn JC. Role of refluxed acid in pathogenesis of laryngeal disorders. *Am J Med* 1997;103(suppl):100S-106S.
- Unge P, Andersson T. Drug interactions with proton pump inhibitors. *Drug Safety* 1997;16:171-179.
- Van der Veen AH, Dees J, Blankensteijn JD, et al. Adenocarcinoma in Barrett's esophagus: An overrated risk. *Gut* 1989;30:14-18.
- Van Rensburg CJ, Honiball PJ, Van Zyl JH, et al. Safety and efficacy of pantoprazole 40 mg daily as relapse prophylaxis in patients with healed reflux oesophagitis: A 2 year follow-up. *Aliment Pharmacol Ther* 1999;13:1023-1028.
- Van Sandick JW, Lanschot JB, Kuiken BW, et al. Impact of endoscopic biopsy surveillance of Barrett's esophagus on pathological stage and clinical outcome of Barrett's carcinoma. *Gut* 1998;43:216-222.
- Vicari F, Belin J, Marek L, et al. Pantoprazole 40 mg versus omeprazole 20 mg in the treatment of reflux oesophagitis: Results of a French multicentre double-blind comparative trial. *Gastroenterology* 1998;114:A324 [Abstract].
- Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA-positive *Helicobacter pylori* strains in the spectrum of gastroesophageal reflux disease. *Gastroenterology* 1998;115:50-57.
- Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. *N Engl J Med* 1995;333:1106-1110.

... BIBLIOGRAPHY ...

- Waring JP, Eastwood TF, Austin JM, et al. The immediate effects of cessation of cigarette smoking on gastroesophageal reflux. *Am J Gastroenterol* 1989;84:1076-1078.
- Weiner GJ, Morgan TM, Copper JB, et al. Ambulatory 24 hour esophageal pH monitoring: Reproducibility and variability of pH parameters. *Dig Dis Sci* 1988;33:1127-1133.
- Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. *J Am Pharm Assoc* 2000;40(1):52-62.
- Weston AP, Badr AS, Hassanein RS. Prospective multivariate analysis of factors predictive of complete regression of Barrett's esophagus. *Am J Gastroenterol* 1999;94:3420-3426.
- Wilkinson SP, Biddlestone L, Gore S, Shepherd A. Regression of columnar-lined Barrett's esophagus with omeprazole 40 mg daily: Results of 5 years of continuous therapy. *Aliment Pharmacol Ther* 1999;13:1205-1209.
- Williams MP, Pounder RE. Review article: The pharmacology of rabeprazole. *Aliment Pharmacol Ther* 1999;13(suppl 3):3-10.
- Witzel L, Gutz H, Huttemann W, et al. Pantoprazole versus omeprazole in the treatment of acute gastric ulcers. *Aliment Pharmacol Ther* 1995;9:19-24.
- Wurzer H, Schutze K, Bethke T, et al. Efficacy and safety of pantoprazole in patients with gastroesophageal reflux disease using an intravenous-oral regimen. Austrian intravenous pantoprazole study group. *Hepatogastroenterology* 1999;46:1809-1815.
- Zagari M, Villa KF, Freston JW. Proton pump inhibitors versus H2-receptor antagonists for the treatment of erosive gastroesophageal reflux disease: A cost-comparative study. *Am J Manag Care* 1995;1:247-255.

...NOTES...

... NOTES ...